By exploiting the genetic variation in cancer cells, an already approved cancer drug demonstrated enhanced effects against ...

Among the most promising was a clinically approved drug called talazoparib, which consistently showed a heightened cytotoxic effect against liver cancer cells that lacked ... Genetics and Pathology, ...

Hirst III Professor of Oncology in Pathology and a member of ... targets by studying what goes wrong in the liver's healing mechanisms that lead to cancer. Prior research has found that levels ...

Hirst III Professor of Oncology in Pathology and member of ... targets by studying what goes wrong in the liver's healing mechanisms that leads to cancer. Prior research has found that levels ...

According to Headline results from part 1 of the phase 3 ESSENCE trial, Semaglutide 2.4 mg may significantly improve liver ...

Novo Nordisk today announced the headline results from part 1 of the ongoing ESSENCE trial, a pivotal phase 3, 240-week, ...

Teamwork: A Multidisciplinary Approach to Early Lung Cancer: Beyond Standard of Care NYU lung cancer specialists discuss advances in adjuvant therapy for non–small cell lung cancer, including ...

First patients dosed in Phase 3 SYNCHRONYOutcomes study of lead candidate efruxifermin (EFX) in patients with compensated cirrhosis (F4) due to ...

Ravi B Parikh, MD, MPP discusses the current and future use of artificial intelligence (AI) in the greater US health care ...

More specifically, digital pathology means that a tissue sample is first ... for example, the bones, lungs or liver. Disseminated breast cancer is currently incurable, so the aim is to slow down the ...